These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 24111619)

  • 21. Do we need to screen for de-novo diabetes mellitus in chronic hepatitis C patients after a sustained virological response?
    Mousa N; Abdel-Razik A; Farag R; Shabana W; Elgamal A; El-Wakeel N; Elzehery R; Elkashef W; Eldars W
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1004-1009. PubMed ID: 28749790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Type 2 diabetes mellitus, insulin resistance and hepatocellular carcinoma in chronic hepatitis C patients.
    Lombay B; Szilágyi R; Szalay F
    Orv Hetil; 2019 Oct; 160(40):1591-1602. PubMed ID: 31565976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [[Insulin-dependent diabetes mellitus as a possible sequelae of treatment of viral hepatitis with interferon-alpha] ].
    Petrovicová A
    Epidemiol Mikrobiol Imunol; 2000 Nov; 49(4):158-61. PubMed ID: 11188763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon-gamma inhibits interferon-alpha signalling in hepatic cells: evidence for the involvement of STAT1 induction and hyperexpression of STAT1 in chronic hepatitis C.
    Radaeva S; Jaruga B; Kim WH; Heller T; Liang TJ; Gao B
    Biochem J; 2004 Apr; 379(Pt 1):199-208. PubMed ID: 14690454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diabetes mellitus during interferon therapy for chronic viral hepatitis.
    Mofredj A; Howaizi M; Grasset D; Licht H; Loison S; Devergie B; Demontis R; Cadranel JF
    Dig Dis Sci; 2002 Jul; 47(7):1649-54. PubMed ID: 12141831
    [No Abstract]   [Full Text] [Related]  

  • 26. Interferon-associated retinopathy in a uniform regimen of natural interferon-alpha therapy for chronic hepatitis C.
    Saito H; Ebinuma H; Nagata H; Inagaki Y; Saito Y; Wakabayashi K; Takagi T; Nakamura M; Katsura H; Oguchi Y; Ishii H
    Liver; 2001 Jun; 21(3):192-7. PubMed ID: 11422782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin resistance and response to antiviral therapy in chronic hepatitis C: mechanisms and management.
    del Campo JA; López RA; Romero-Gómez M
    Dig Dis; 2010; 28(1):285-93. PubMed ID: 20460925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trajectories of anti-islet autoantibodies before development of type 1 diabetes in interferon-treated hepatitis C patients. Case reports and a literature review.
    Nakamura K; Kawasaki E; Abiru N; Jo O; Fukushima K; Satoh T; Kuriya G; Kobayashi M; Kuwahara H; Yamasaki H; Ide T; Eguchi K
    Endocr J; 2010; 57(11):947-51. PubMed ID: 20805634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin resistance and hepatitis C.
    Romero-Gómez M
    World J Gastroenterol; 2006 Nov; 12(44):7075-80. PubMed ID: 17131467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy.
    Persico M; Capasso M; Persico E; Svelto M; Russo R; Spano D; Crocè L; La Mura V; Moschella F; Masutti F; Torella R; Tiribelli C; Iolascon A
    Hepatology; 2007 Oct; 46(4):1009-15. PubMed ID: 17668875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism.
    Carella C; Mazziotti G; Morisco F; Rotondi M; Cioffi M; Tuccillo C; Sorvillo F; Caporaso N; Amato G
    Eur J Endocrinol; 2002 Jun; 146(6):743-9. PubMed ID: 12039693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Augmentation of the immune response to islet cell antigens with development of diabetes mellitus caused by interferon-alpha therapy in chronic hepatitis C].
    Seifarth C; Benninger J; Böhm BO; Wiest-Ladenburger U; Hahn EG; Hensen J
    Z Gastroenterol; 1999 Mar; 37(3):235-9. PubMed ID: 10234796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapidly reversible increase in insulin requirement with interferon.
    Campbell S; Mclaren EH; Danesh BJ
    BMJ; 1996 Jul; 313(7049):92. PubMed ID: 8688762
    [No Abstract]   [Full Text] [Related]  

  • 34. [Onset of type 1 diabetes mellitus during combination therapy of chronic hepatitis C with interferon-alpha and ribavirin].
    Christensen UB; Krogsgaard K
    Ugeskr Laeger; 2004 Mar; 166(11):1024-5. PubMed ID: 15049242
    [No Abstract]   [Full Text] [Related]  

  • 35. [Type 1 diabetes developing during alpha-interferon therapy: report of two cases].
    Vinagre I; Rigla M; Torras X; Enríquez J; Corcoy R
    Endocrinol Nutr; 2010 Oct; 57(8):393-5. PubMed ID: 20462813
    [No Abstract]   [Full Text] [Related]  

  • 36. Insulin resistance among patients with chronic hepatitis C: etiology and impact on treatment.
    Harrison SA
    Clin Gastroenterol Hepatol; 2008 Aug; 6(8):864-76. PubMed ID: 18585970
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of reversible diabetes mellitus after cessation of interferon-alpha therapy for chronic hepatitis C infection.
    Tasi TN; Hsieh CH
    N Z Med J; 2004 Dec; 117(1207):U1230. PubMed ID: 15608817
    [No Abstract]   [Full Text] [Related]  

  • 38. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis.
    Fabris P; Betterle C; Greggio NA; Zanchetta R; Bosi E; Biasin MR; de Lalla F
    J Hepatol; 1998 Mar; 28(3):514-7. PubMed ID: 9551692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The treatment of HCV infection with interferon alpha and ribavirin in a child with diabetes I type].
    Jasonek J; Kacprzak-Bergman I; Zaleska I
    Przegl Epidemiol; 2006; 60(2):259-63. PubMed ID: 16964677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus.
    Carper MJ; Cade WT; Cam M; Zhang S; Shalev A; Yarasheski KE; Ramanadham S
    Am J Physiol Endocrinol Metab; 2008 Mar; 294(3):E558-67. PubMed ID: 18171911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.